目的:探讨拉贝洛尔联合硝苯地平对原发性高血压患者临床疗效观察及对患者炎性因子和凝血功能的影响。方法:选择浙江省荣军医院2017年12月至2018年12月收治的原发性高血压患者142例，按照随机数字表法分为对照组71例与观察组71例。对照组患者采用硝苯地平治疗，观察组在对照组基础上联合拉贝洛尔治疗。两组疗程均为3个月。比较两组治疗疗效，治疗前后血压、炎性因子和凝血功能水平变化，及不良反应。结果:观察组总有效率(90.14%)高于对照组(73.24%)(χn 2＝6.780，n P<0.05)。两组治疗后舒张压(DBP)和收缩压(SBP)均较治疗前降低(观察组：n t＝24.544、19.890，对照组：n t＝14.473、19.273，均n P<0.05)；观察组治疗后DBP和SBP均低于对照组(n t＝8.756、6.892，均n P<0.05)。两组治疗后血清白细胞介素6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子α(TNF-α)水平均较治疗前降低(观察组：n t＝15.125、20.859、22.729，对照组：n t＝7.784、10.865、10.418，均n P<0.05)；观察组治疗后血清IL-6、CRP和TNF-α水平均低于对照组(n t＝15.145、7.662、13.692，均n P<0.05)。两组治疗后血浆D-二聚体和纤维蛋白原(Fib)水平均较治疗前降低(观察组：n t＝14.655、18.707，对照组：n t＝8.728、7.269，均n P<0.05)；观察组治疗后血浆D-二聚体和Fib水平均低于对照组(n t＝9.384、10.831，均n P0.05)。n 结论:拉贝洛尔联合硝苯地平对原发性高血压患者临床疗效良好，可减轻炎性反应，改善患者凝血功能，值得临床借鉴。“,”Objective:To investigate the clinical efficacy of labetalol combined with nifedipine in the treatment of patients with essential hypertension and its influence on inflammatory factors and coagulation function.Methods:From December 2017 to December 2018, 142 patients with essential hypertension admitted to Rongjun Hospital of Zhejiang Province were divided into control group (71 cases) and observation group (71 cases) according to random number table method.The patients in the control group were treated with nifedipine, while patients in the observation group were treated with labetalol on the basis of the control group.Both two groups were treated for 3 months.The therapeutic effect, changes of blood pressure, inflammatory factors, coagulation function and adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the observation group (90.14%) was higher than that of the control group (73.24%) (χn 2=6.780, n P<0.05). After treatment, the diastolic blood pressure(DBP) and systolic blood pressure(SBP) in the two groups were lower than those before treatment (observation group:n t=24.544, 19.890, control group: n t=14.473, 19.273, all n P<0.05). After treatment, the DBP and SBP in the observation group were lower than those in the control group (n t=8.756, 6.892, all n P<0.05). After treatment, the serum levels of IL-6, C-reactive protein (CRP) and TNF-α in the two groups were lower than those before treatment (observation group:n t=15.125, 20.859, 22.729, control group: n t=7.784, 10.865, 10.418, all n P<0.05). After treatment, the serum levels of IL-6, CRP and TNF-α in the observation group were lower than those in the control group (n t=15.145, 7.662, 13.692, all n P<0.05). After treatment, the plasma D-dimer and Fib levels in the two groups were lower than before treatment (observation group:n t=14.655, 18.707, control group: n t=8.728, 7.269, all n P<0.05). After treatment, the plasma D-dimer and Fib levels in the observation group were lower than those in the control group (n t=9.384, 10.831, all n P0.05).n Conclusion:Labetalol combined with nifedipine has good clinical efficacy in treating essential hypertension, alleviating inflammation and improving coagulation function, which is worthy of clinical reference.